Previous 10 | Next 10 |
SOLANA BEACH, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced enrollment of the first patient in a Glioblastoma clinical trial ...
Summary Lower revenue growth in 3Q22 was a result of the postponement of case surgeries and lumpiness in B&DD revenue. Based on FY22 revenue guidance, growth is likely to push back to 4Q22. The company has a strong balance sheet to fund its high operating losses in the nea...
SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the following investor ...
ClearPoint Neuro, Inc. (CLPT) Q3 2022 Earnings Conference Call November 8, 2022 04:30 PM ET Company Participants Joe Burnett - CEO Danilo D’Alessandro - CFO Conference Call Participants William Wood - B. Riley Frank Takkinen - Lake Street Capit...
ClearPoint Neuro press release ( NASDAQ: CLPT ): Q3 GAAP EPS of -$0.15. Revenue of $5.1M vs $4.6M. CLPT reaffirmed full year 2022 revenue outlook of between $21.0 and $22.0M. Cash and short-term investments totaled $40.5M as of Sept 30, 2022. CLPT said three new pr...
SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September ...
ClearPoint Neuro ( NASDAQ: CLPT ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, after market close. The consensus EPS Estimate is -$0.19 (-5.6% Y/Y) and the consensus Revenue Estimate is $5.41M (+17.6% Y/Y). Over the last 3 months, EPS estimate...
SOLANA BEACH, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 third q...
ClearPoint Neuro ( NASDAQ: CLPT ) said its Swedish partner Clinical Laserthermia Systems (CLS) received the U.S. Food and Drug Administration's (FDA)510(k) clearance for its laser system to necrotize or coagulate soft tissue through interstitial irradiation or th...
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced its Swedish partner, Clinical Laserthermia Systems (CLS), ...
News, Short Squeeze, Breakout and More Instantly...
ClearPoint Neuro, Inc. Company Name:
CLPT Stock Symbol:
NASDAQ Market:
ClearPoint Neuro, Inc. Website:
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its ...
2024-07-15 17:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...